



SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

Date: 14.8.2025

Head Listing & Compliance
Metropolitan Stock Exchange of India Limited
205(A), 2nd floor, Piramal Agastya Corporate Park,
Kamani Junction, LBS Road,
Kurla (West), Mumbai – 400070
Dear Sir,

Sub: Submission of unaudited financial results of the Company for the quarter ended 30th June, 2025 along with the Limited review report - Reg.

Ref: Disclosure under Regulation 30 & 33 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Reg.

Pursuant to Regulation 33 and Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at its Meeting held today i.e., on Thursday, 14th August, 2025 had inter-alia considered transacted and approved the following items of business:

1. Approved the unaudited financial results along with Segment Results for the quarter ended 30th June, 2025 with limited review report issued by the statutory auditors'.
2. Based on the recommendation of the Nomination and remuneration Committee, the board recommended the reappointment of Sri. T. Adinarayana (DIN: 00917498) as Non-Executive Non Independent director of the company, who retires by rotation and eligible for reappointment subject to the approval of shareholders at the ensuing Annual General Meeting.
3. Based on recommendation of the Nomination and remuneration Committee, the board recommended the appointment of Dr. Govindarajula Venkata Narasimha Rao (DIN: 02391404), as an independent director of the company for a period of five consecutive years with effect from 27.9.2025, subject to the approval of shareholders at the ensuing AGM of the company.
4. Approved the Secretarial Audit Report for the year ended 31.3.2025 issued by Secretarial Auditors' of the company.
5. Approved the Directors report along with the annexures'.
6. Approved the Notice of the 31st Annual General Meeting and the AGM will be held on Saturday, the 27th day of September, 2025 at 4.00 P.M., through Video Conferencing (VC) / Other Audio Visual Means ('OAVM') and also approved the Annual Report for the year 2024 - 2025.

LEKHA SAI
SURAPANE
NI

Digitally signed by LEKHA SAI
SURAPANE
DN: c=IN, o=Personal,
postalCode=500033, st=Telangana,
serialNumber=A1D0E6A3442B6566
5964A596C8B873ED72FE0B483383
EFAD7BF4D82DB298AB, cn=LEKHA
SAI SURAPANE
Date: 2025.08.14 18:33:36 +05'30'



SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001. Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

7. The Register of Members and Share Transfer Registers will be closed from Sunday, 21st September, 2025 to Saturday, 27th September, 2025 (both the days inclusive) and the record date (cut-off date) will be 20th September, 2025.

8. The board has appointed Mr. D. Venkata Ratnam, Chartered Accountant, Proprietor of M/s. Venkataratnam & Associates, Chartered Accountants as Scrutinizer for the 31st AGM to be held on 27.9.2025.

9. In pursuance of the disclosure made under regulation 30 of SEBI (LODR) Regulations, 2015 on 28.3.2025 by the board of Directors, we wish to inform that in partial modification of the resolution passed on 28.3.2025, the board has considered and approved the Purchase of Semi-finished Flat in a multi storied complex which is under construction admeasuring 5045 sqft., bearing number B-2204, along with 3 car parking spaces, in ENCANTO by LANSUM AND MK Realty situated at S No. 347P, 358, 349 and 350 of Puppalaguda, Gandipet Mandal, Ranga Reddy District, Hyderabad for a consideration of Rs. 1,81,62,000/- for semi-finished flat plus applicable GST, Registration charges, Corpus fund and other charges as applicable. The company has paid a total consideration to Mrs. Sanjana Chowdhary katru and the board has authorized Sri. T. Raja Sekhar, Executive Director of the company, to represent on behalf of the company at the time of registration of the Flat and do all other acts and deeds in this regard. A disclosure under applicable regulations of SEBI and SEBI Circulars is disclosed as Annexure C.

Further the board has noted that the second term of Mr. T. Govardhana Rao (DIN: 07162634) as an Independent Director of the company will come to an end on 28.9.2025 and as such the board keeps on record its appreciation for his services and guidance during his tenure as an Independent Director of the company.

Accordingly, please find enclosed herewith the following:

1. Un-Audited financial Results along with segment results and Limited Review Report for the quarter ended 30th June, 2025.
2. Annexure - A relating to Sri. T. Adinarayana, proposed to be reappointed as the Director of the Company liable to retire by rotation, subject to the approval of members at the ensuing 31st Annual General Meeting.
3. Annexure – B relating to Dr. Govindarajula Venkata Narasimha Rao, proposed to be appointed as the Independent Director of the Company subject to the approval of members at the ensuing 31st Annual General Meeting.

LEKHA SAI
SURAPAN
ENI

Digitally signed by LEKHA SAI
SURAPANENI
DN: cn=LEKHA SAI SURAPANENI,
o=Personal,
postalCode=500033, st=Telangana,
serialNumber=A1DDE6EA34428E6
4655648596C8B773D72FED0B48
3383EFAD1BF4D82B298AB,
cn=LEKHA SAI SURAPANENI
Date: 2025.08.14 18:33:58 +05'30'



SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001. Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

4. Annexure - C relating to disclosure under applicable regulations of SEBI and SEBI Circulars for purchase of Semi-finished Flat.

Further we wish to inform that following regulations are not applicable to our company:

- a. The company do not have any Non-convertible Instruments (Debt), as such Reg. 52(4) & 52(6) SEBI (LODR) Regulations, 2015 is not applicable to the company.
- b. Reg. 54(2)/(3) SEBI (LODR) Regulations, 2015 – No security cover created as we do not have any secured listed non - convertible debt Instruments.

Kindly take the above on your records.

Thanking you,

Yours faithfully,

For Sigachi Laboratories Limited

**LEKHA SAI
SURAPANE
NI**

Digitally signed by LEKHA SAI
SURAPANENI
DN: cn=NI, o=Personal,
postalCode=500033, st=Telangana,
serialNumber=A1DDE6EA3442BE64
65964A596CBB873ED72FE0DB4B33
83EFAD1BF4D82DB298AB,
cn=LEKHA SAI SURAPANENI
Date: 2025.08.14 18:34:16 +05'30'

(Lekha Sai Surapaneni)
Company Secretary

The meeting Commenced at 4:00 PM

The Meeting Concluded at 6:30 PM



SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001. Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

Annexure A

Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Reappointment of Sri. T. Adinarayana (DIN: 00917498), as Non-Executive Non Independent director of the company of the Company:

a.	Reason for change viz. appointment, reappointment resignation, removal, death or otherwise	Sri. T. Adinarayana, who retires by rotation and being eligible, offers himself for reappointment as Non-Executive and Non-Independent Director. Based on the recommendation of Nomination and Remuneration Committee, the Board of Directors recommends his appointment, which is subject to the approval of members at the ensuing Annual General Meeting of the company.
b.	Date of appointment/ reappointment/cessation (as applicable) & term of appointment/reappointment;	Appointed by members at the 29 th AGM held on 27 th September, 2023, liable to retire by rotation.
c.	Brief profile (in case of appointment);	He has about 9 Years of experience in A.P. State Financial Corporation, and about 8 years' experience as a Chartered Accountant earlier and about 20 years' experience in the company as a Managing Director. After his resignation as Managing Director of the company and since then, 2018, he is practicing as a Chartered Accountant.
d.	Disclosure of relationships between directors (in case of appointment of a director)	He is the Father of Sri. T.R. Sekhar, Executive Director of the company. There are no other inter se relations between the appointee and the other members of the Board or Senior Management and KMP's of the Company.
e.	Disclosure pursuant to BSE Circular No. LIST/COMP/14/2018-19 dated June 20, 2018	Sri. T. Adinarayana is not debarred from holding the office of director pursuant to any SEBI order or any such authority.

LEKHA SAI
SURAPAN
ENI

Digitally signed by LEKHA SAI
SURAPANENI
DN: cn=IN, o=Personal,
postalCode=500033,
st=Telangana,
serialNumber=A1DD6EA3442B
E6465964A596CBB873ED72FEO
D84B3383EFA11BF4D82D8298
AD, cn=LEKHA SAI SURAPANENI
Date: 2025.08.14 18:34:34
+05'30'



SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

Annexure B

Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Appointment of Dr. Govindarajula Venkata Narasimha Rao (DIN: 02391404), as an Independent director of the company of the Company:

a.	Reason for change viz. appointment, reappointment, resignation, removal, death or otherwise	Based on the recommendation of Nomination and Remuneration Committee, the Board of Directors recommends the appointment of Dr. Govindarajula Venkata Narasimha Rao (DIN: 02391404) aged about 70 years, as an Independent Director of the company, which is subject to the approval of members at the ensuing Annual General Meeting of the company.
b.	Date of appointment/reappointment/cessation (as applicable) & term of appointment/reappointment;	The appointment of Dr. Govindarajula Venkata Narasimha Rao (DIN: 02391404) as an Independent Director of the company is for term of five consecutive years with effect from 27.9.2025.
c.	Brief profile (in case of appointment);	He is fellow member of Institute of Cost Accountants of India and has about 14 years of rich Experience in A.P. State Financial Corporation as Manager. He had worked about 18 years as Senior Vice President - Finance in M/s. Soma Enterprise Ltd., and at present he is practicing as an Insolvency Professional (IP) since about 7 years. Earlier he has also worked as accounts officer for Dredging Corporation of India Limited for about 3 years. He also did his Doctorate in Management.
d.	Disclosure of relationships between directors (in case of appointment of a director)	There are no inter se relations between the appointee and the other members of the Board or Senior Management and KMP's of the Company.
e.	Disclosure pursuant to BSE Circular No. LIST/COMP/14/2018-19 dated June 20, 2018	Dr. Govindarajula Venkata Narasimha Rao is not debarred from holding the office of director pursuant to any SEBI order or any such authority.

LEKHA SAI
SURAPANE
NI

Digitally signed by LEKHA SAI SURAPANE
DN: cn=Personal, postalCode=500033, st=Telangana, serialNumber=A1D06EA3428E646, email=SURAPANE@SIGACHI.LABORATORIES.CO.IN, c=IN, o=SIGACHI LABORATORIES LIMITED, ou=LEKHA SAI SURAPANE
Date: 2025.08.14 18:34:53 +05'30'



SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

Annexure - C

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Purchase of Property:

Details of Counterparties (including name and relationship with the listed entity)	Name: 1. Sanjana Chowdhary Katru and Lansum & MK Realty LLP Relationship: No relationship of our company with promoter/promoter group/group companies/LLP's/Firms.
Purpose of entering into the agreement	To purchase the property for office purpose.
Shareholding, if any, in the entity with whom the agreement is executed	No shareholding/partnership in the entity/individual with whom the agreement is executed.
Significant terms of the agreement (in brief)	Address of Property: at S No. 347P, 358, 349 and 350 of Puppalaguda, Gandipet Mandal, Ranga Reddy District, Hyderabad. - Property Details: Semi-finished Flat in a multi storied complex which is under construction admeasuring 5045 sqft., bearing number B-2204, along with 3 car parking spaces. Purchase consideration: Rs. 1,81,62,000/- for semi-finished flat, plus applicable GST, Registration charges, Corpus fund and other charges as applicable and the total amount is paid to Mrs. Sanjana Chowdhary katru. Source of funds: Internal Accruals.
Extent and the nature of impact on management or control of the listed entity	Not Applicable
Whether the said parties are related to promoter/promoter group/group companies in any manner. If yes, nature of relationship;	No promoter/promoter group/group companies in any manner are a related party.
Whether the transaction would fall within the related party transactions? If yes, whether the same is done at "arm's length"	Not applicable

LEKHA SAI
SURAPAN
ENI

Digitally signed by LEKHA SAI
SURAPANENI
DN: cn=IN, o=Personal,
postalCode=500033,
st=Telangana,
serialNumber=A1DDE6EA3442BE
6465964A596CB8873ED72FE0DB
4B3383EFAD1BF4D82DB298AB,
cn=LEKHA SAI SURAPANENI
Date: 2025.08.14 18:35:14 +05'30'

SIGACHI LABORATORIES LIMITED

Regd. Office: S.No: 530 & 534, Bonthapally - 502 313, Gummadidala Mandal, Sanga Reddy District, Telangana.

Tel No.: 040 - 23204230/23204273

Website:www.slllab.com, Email:sigachilaboratories@yahoo.co.in

CIN: L24230TG1994PLC018786

Statement of Unaudited Financial Results For the Quarter Ended 30th June, 2025

(Rs. in Lakhs)

Sl.No.	Particulars	Quarter ended			Year ended	
		30.06.2025	31.03.2025	30.06.2024	31.03.2025	
		(Unaudited)	(Audited)	(Unaudited)	(Audited)	
	Income					
1	Revenue from operations	127.76	63.88	140.24	312.23	
2	Other income	21.71	17.03	1.60	65.95	
3	Total Income (1+2)	149.47	80.91	141.84	378.18	
4	Expenses					
	a) Cost of materials consumed	-	-	-	-	
	b) Purchase of Stock-in-Trade	-	-	-	-	
	c) Impairment on Advances	-	75.00	-	75.00	
	d) Fair Value Loss	-	68.77	-	68.77	
	e) Employee benefits expense	10.51	11.36	10.09	42.90	
	f) Finance costs	-	-	-	-	
	g) Depreciation and amortization expense	5.78	5.79	5.30	23.17	
	h) Other expenses	3.87	5.47	4.30	16.12	
	Total Expenses	20.16	166.39	19.69	225.96	
5	Profit/(Loss) before exceptional items and tax (3-4)	129.31	(85.48)	122.15	152.22	
6	Exceptional Items	-	-	-	-	
7	Profit/(Loss) before tax (5-6)	129.31	(85.48)	122.15	152.22	
8	Tax expense					
	(a) Current tax	10.61	14.28	4.58	45.61	
	(b) Deferred tax	9.70	(9.49)	(8.45)	(12.49)	
	Total Tax Expense	20.31	4.79	(3.87)	33.12	
9	Profit/(Loss) for the Period (7-8)	109.00	(90.27)	126.02	119.10	
10	Other Comprehensive income (OCI)					
	(a) Items that will not be reclassified to profit or (loss)	206.16	(172.02)	274.61	247.67	
	(b) Remeasurement gains/(losses) on defined benefit plans	-	0.57	-	0.57	
	(c) Tax on Items that will not be reclassified to profit or (loss)	(29.48)	24.50	(28.56)	(35.52)	
	(d) Items that will be reclassified to profit or (loss)	-	-	-	-	
	(e) Items that may be reclassified subsequently to profit or (loss)	-	-	-	-	
	Total other Comprehensive income for the period, net of tax	176.68	(146.95)	246.05	212.72	
	Total Comprehensive income (9+10)	285.68	(237.22)	372.07	331.82	
11	Paid-up Equity Share Capital (Face Value of Rs.10/- each)	675.31	675.31	675.31	675.31	
12	Other Equity	-	-	-	3,201.66	
13	Earnings per equity share (of Rs.10/- each) (not annualized (in Rs.))					
	(1) Basic	1.61	(1.34)	1.87	1.76	
	(2) Diluted	1.61	(1.34)	1.87	1.76	

Segment wise Revenue, Results and Capital Employed for the Quarter Ended 30th June, 2025

(Rs. in Lakhs)

Sl.No	Particulars	Quarter ended			Year ended
		30.06.2025	31.03.2025	30.06.2024	31.03.2025
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Segment Revenue				
	a) Bulk Drugs and Intermediates (Lease Rents)	25.00	48.00	23.00	140.50
	b) Investments	124.47	32.91	118.84	237.68
	Total	149.47	80.91	141.84	378.18
	Less: Inter Segment Revenue	-	-	-	-
	Net Sales/Income from Operations	149.47	80.91	141.84	378.18
2	Segment Results Profit/(Loss) before tax and finance costs from each segment				
	a) Bulk Drugs and Intermediates (Lease Rents)	18.68	42.03	17.32	115.42
	b) Investments	124.47	(35.86)	118.84	168.91
	Total	143.15	6.17	136.16	284.33
	Less: (i) Finance Costs	-	-	-	-
	(ii) Other Un-allocable Expenditure net off	13.84	91.65	14.01	132.11
	(iii) Un-allocable income	-	-	-	-
	Total Profit/(loss) Before Tax	129.31	(85.48)	122.15	152.22
3	Capital Employed (Segment Assets – Segment Liabilities)				
	a) Bulk Drugs and Intermediates	699.51	791.09	810.01	791.09
	b) Investments	3,518.90	3,141.63	3,162.96	3,141.63
	Total	4,218.41	3,932.72	3,972.97	3,932.72

Notes :

- 1 The above unaudited Financial results as reviewed and recommended by the Audit Committee are considered and approved by the Board of Directors at their respective meetings held on 14th August, 2025.
- 2 These financial results of the company have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 3 These Financial results have been subjected to limited review by the Statutory Auditors'.
- 4 These Financial Results are available on the Stock Exchange website (www.msei.in) and also on the company's website at (www.slllab.com).

for SIGACHI LABORATORIES LIMITED

(T.R.Sekhar)

Executive Director
DIN:02943146

Tunuguntla Raja Sekhar

Digitally signed by Tunuguntla Raja Sekhar
DN: cn=N, o=Personal, postalCode=560067,
l=Bengaluru, st=Karnataka, street=Villa No 118
Akshaya Redstone, Seegehalli, Bangalore
South Karnataka India 560067 Opposite To
Shell Petrol Bunk, title=6686,
2.5.4.20=7461bd5ea87b477d6b0ef52e96579fd
60f62a2c5846d5eab0c35162bae5a,
serialNumber=68020441af9d262233c7df4ddf
50c34c9458e946eb5f41512c31e9a5d5a805,
email=rajskhar2112@gmail.com,
cn=Tunuguntla Raja Sekhar
Date: 2025.08.14 18:36:10 +05'30'

Place : Hyderabad
Date : 14.08.2025

Independent Auditor's Review Report on the Quarter ended 30th June, 2025 Unaudited Financial Results of the Company pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To The Board of Directors of **SIGACHI LABORATORIES LIMITED**

1. We have reviewed the accompanying statement of unaudited financial results of **SIGACHI LABORATORIES LIMITED** (the Company') for the quarter ended 30th June 2025 attached herewith, being submitted by the Company pursuant to the requirements of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD 1/44/2019 "Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the management and other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Our conclusion on the statement in respect of these matters is not modified with respect to the financial results and other financial information certified by the management.

For M/s. NSVR & ASSOCIATES LLP

Chartered accountants

FRN: 008801S/S2000

V-g



V. Gangadhara Rao

Partner

Membership No: 219486

UDIN: 25249486BMISAU7110

Place: Hyderabad

Date : 14-08-2025

MSEI LTD
ACKNOWLEDGEMENT

Acknowledgement No	: 1408202506430727	Date & Time	: 14/08/2025 18:43:07
Symbol	: SIGACHI		
Entity Name	: SIGACHI LABORATORIES LIMITED		
Compliance Type	: Regulations 33(3) - Integrated Finance IND AS		
Quarter / Period	: 30/06/2025		
Mode	: E-Filing		

General information about company	
Scrip code*	000000
NSE Symbol*	NOTLISTED
MSEI Symbol*	SIGACHI
ISIN*	INE368H01018
Name of company	SIGACHI LABORATORIES LIMITED
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2025
Date of end of financial year	31-03-2026
Date of board meeting when results were approved	14-08-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	04-08-2025
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Quarterly
Reporting Quarter	First quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	
Segment Reporting	Multi segment
Description of single segment	
Start date and time of board meeting	14-08-2025 04:00
End date and time of board meeting	14-08-2025 06:30
Whether cash flow statement is applicable on company	
Type of cash flow statement	
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No
No. of times funds raised during the quarter	
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No NOT TAKEN ANY LOANS FROM ANY ONE

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2025	01-04-2025
Date of end of reporting period		30-06-2025	30-06-2025
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Income		
	Revenue from operations	127.76	127.76
	Other income	21.71	21.71
	Total income	149.47	149.47
2	Expenses		
(a)	Cost of materials consumed	0	0
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0	0
(d)	Employee benefit expense	10.51	10.51
(e)	Finance costs	0	0
(f)	Depreciation, depletion and amortisation expense	5.78	5.78
(g)	Other Expenses		
1	MISCELLANEOUS EXPENSES	0.62	0.62
2	LISTING FEE	0.55	0.55
3	CONVEYANCE EXPENSES	0.5	0.5
4	CUSTODY FEE	0.45	0.45
5	RENT	0.42	0.42
6	INSURANCE	0.37	0.37
7	OFFICE MAINTENANCE	0.24	0.24
8	FACTORY MAINTENANCE	0.18	0.18
9	SHARE TRANSFER FEE	0.17	0.17
10	OTHER EXPENSES	0.37	0.37
	Total other expenses	3.87	3.87
	Total expenses	20.16	20.16
3	Total profit before exceptional items and tax	129.31	129.31
4	Exceptional items	0	0
5	Total profit before tax	129.31	129.31
6	Tax expense		

7	Current tax	10.61	10.61	
8	Deferred tax	9.7	9.7	
9	Total tax expenses	20.31	20.31	
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0	
11	Net Profit Loss for the period from continuing operations	109	109	
12	Profit (loss) from discontinued operations before tax	0	0	
13	Tax expense of discontinued operations	0	0	
14	Net profit (loss) from discontinued operation after tax	0	0	
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0	
16	Total profit (loss) for period	109	109	
17	Other comprehensive income net of taxes	176.68	176.68	
18	Total Comprehensive Income for the period	285.68	285.68	
19	Total profit or loss, attributable to			
	Profit or loss, attributable to owners of parent			
	Total profit or loss, attributable to non-controlling interests			
20	Total Comprehensive income for the period attributable to			
	Comprehensive income for the period attributable to owners of parent			
	Total comprehensive income for the period attributable to owners of parent non-controlling interests			
21	Details of equity share capital			
	Paid-up equity share capital	675.31	675.31	
	Face value of equity share capital	10	10	
22	Reserves excluding revaluation reserve			
23	Earnings per share			
i	Earnings per equity share for continuing operations			
	Basic earnings (loss) per share from continuing operations	1.61	1.61	
	Diluted earnings (loss) per share from continuing operations	1.61	1.61	
ii	Earnings per equity share for discontinued operations			
	Basic earnings (loss) per share from discontinued operations	0	0	
	Diluted earnings (loss) per share from discontinued operations	0	0	
iii	Earnings per equity share (for continuing and discontinued operations)			
	Basic earnings (loss) per share from continuing and discontinued operations	1.61	1.61	
	Diluted earnings (loss) per share from continuing and discontinued operations	1.61	1.61	
24	Debt equity ratio			Textual Information(1)
25	Debt service coverage ratio			Textual Information(2)

26	Interest service coverage ratio			Textual Information(3)
27	Disclosure of notes on financial results	Textual Information(4)		

Text Block

Textual Information(4)

1. The above unaudited Financial results as reviewed and recommended by the Audit Committee are considered and approved by the Board of Directors at their respective meetings held on 14th August, 2025.
2. These financial results of the company have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
3. These Financial results have been subjected to limited review by the Statutory Auditors'.
4. These Financial Results are available on the Stock Exchange website (www.msei.in) and also on the company's website at (www.slllab.com).

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results			
Particulars	3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	
Date of start of reporting period	01-04-2025	01-04-2025	
Date of end of reporting period	30-06-2025	30-06-2025	
Whether results are audited or unaudited	Unaudited	Unaudited	
Nature of report standalone or consolidated	Standalone	Standalone	
1 Segment Revenue (Income)			
(net sale/income from each segment should be disclosed)			
1	Bulk Drugs and Intermediates (Lease Rents)	25	25
2	Investments	124.47	124.47
	Total Segment Revenue	149.47	149.47
	Less: Inter segment revenue	0	0
	Revenue from operations	149.47	149.47
2 Segment Result			
Profit (+) / Loss (-) before tax and interest from each segment			
1	Bulk Drugs and Intermediates (Lease Rents)	18.68	18.68
2	Investments	124.47	124.47
	Total Profit before tax	143.15	143.15
	i. Finance cost	0	0
	ii. Other Unallocable Expenditure net off Unallocable income	13.84	13.84
	Profit before tax	129.31	129.31
3 (Segment Asset - Segment Liabilities)			
Segment Asset			
1	Bulk Drugs and Intermediates (Lease Rents)	905	905
2	Investments	3518.9	3518.9
	Total Segment Asset	4423.9	4423.9
	Un-allocable Assets	0	0
	Net Segment Asset	4423.9	4423.9
4 Segment Liabilities			
Segment Liabilities			
1	Bulk Drugs and Intermediates (Lease Rents)	205.49	205.49
2	Investments	0	0
	Total Segment Liabilities	205.49	205.49
	Un-allocable Liabilities	0	0
	Net Segment Liabilities	205.49	205.49
Disclosure of notes on segments			

Other Comprehensive Income				
		Date of start of reporting period	01-04-2025	01-04-2025
		Date of end of reporting period	30-06-2025	30-06-2025
		Whether results are audited or unaudited	Unaudited	Unaudited
		Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]			
1	Amount of items that will not be reclassified to profit and loss			
1	ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS		206.16	206.16
	Total Amount of items that will not be reclassified to profit and loss		206.16	206.16
2	Income tax relating to items that will not be reclassified to profit or loss		29.48	29.48
3	Amount of items that will be reclassified to profit and loss			
	Total Amount of items that will be reclassified to profit and loss			
4	Income tax relating to items that will be reclassified to profit or loss		0.00	0.00
5	Total Other comprehensive income		176.68	176.68

